Glioblastoma Multiforme (GBM) Treatment Market Outlook Highlights Strategic Opportunities Across The Industry

The landscape of glioblastoma multiforme (GBM) treatment is evolving swiftly as new therapies and technologies emerge to address this aggressive brain cancer. With ongoing advancements and increasing research efforts, the market for GBM treatments is poised for substantial growth over the coming years. Let's explore the market's size, key players, driving trends, and segmentation in detail.

Anticipated Growth in the Glioblastoma Multiforme Treatment Market by 2030
The global market for glioblastoma multiforme treatment is set to expand significantly, reaching a value of $4.46 billion by 2030. This represents a compound annual growth rate (CAGR) of 10.2% during the forecast period. The surge is largely fueled by breakthroughs in targeted therapies, a growing pipeline of immunotherapy options, increasing adoption of precision medicine, heightened clinical trial activities, and greater research funding. Notable trends shaping market dynamics include wider use of multimodal treatment strategies, enhanced adoption of tumor treating field (TTF) therapy, a sharper focus on personalized treatments specific to GBM, an expansion in immunotherapy methods, and improved strategies for post-surgical care.

The glioblastoma multiforme (gbm) treatment market size has grown rapidly in recent years. It will grow from $2.73 billion in 2025 to $3.02 billion in 2026 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to limited survival outcomes, reliance on surgery and radiation, chemotherapy standardization, growth of neuro-oncology centers, increased brain tumor diagnosis.

Download a free sample of the glioblastoma multiforme (gbm) treatment market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8803&type=smp&utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR

Prominent Corporations Leading the Glioblastoma Multiforme Treatment Industry
Key players contributing to advancements and market presence in GBM treatment include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, Loxo Oncology Inc., Karyopharm Therapeutics Inc., EnGeneIC Ltd., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc, Angiochem Inc., and Diffusion Pharmaceuticals Inc.

In a significant move in October 2024, Merck & Co., a US pharmaceutical company known for its prescription medicines and vaccines, acquired Modifi Biosciences. While the financial details were not disclosed, this acquisition aims to bolster Merck's oncology portfolio by incorporating Modifi's preclinical small-molecule platform. This technology targets cancer cells with DNA repair deficiencies, including those that lack the O6-methylguanine-DNA methyltransferase (MGMT) protein, showing promise against challenging tumors such as glioblastoma. Modifi Biosciences is also based in the US and specializes in treatments targeting GBM.

View the full glioblastoma multiforme (gbm) treatment market report:
https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-gbm-treatment-global-market-report?utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends Driving Innovation in Glioblastoma Multiforme Treatment
Industry leaders are dedicating efforts toward developing advanced wearable and portable devices that offer patients more convenience and improved therapeutic options. These innovations are designed to enhance accessibility to treatment and increase patient comfort while maintaining effectiveness. For example, in 2023, Novocure, an oncology firm based in Jersey, introduced Optune Gio, a portable and wearable device for newly diagnosed glioblastoma patients. Approved by the FDA, Optune Gio uses Tumor Treating Fields (TTFields) technology, which involves alternating electric fields that disrupt the division of cancer cells, potentially prolonging survival.

Another important aspect of Optune Gio is its lightweight design, weighing only 2.7 pounds, which allows patients to wear it comfortably throughout daily activities, reflecting a patient-centered approach in device innovation.

Glioblastoma Multiforme Treatment Market Segmentation and Forecast
The glioblastoma multiforme treatment market is analyzed across several key segments as follows:

By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, and Immunotherapy
By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, and other drug categories
By Route of Administration: Oral, Parenteral, and other delivery methods
By End-Use Settings: Hospitals, Clinics, and Ambulatory Surgical Centers

Further breakdown includes:
Surgery subdivided into tumor resection and biopsy procedures
Radiation therapy split into external beam radiation therapy (EBRT) and stereotactic radiation therapy
Chemotherapy categorized into standard and combination regimens
Immunotherapy divided into checkpoint inhibitors and vaccine-based treatments

This detailed segmentation highlights the comprehensive approach to treating GBM and reflects the diversity of therapeutic options and care settings that contribute to the market's growth.

Our 2026 market reports now offer broader strategic coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.